Invesco Bloomberg Analyst Rating Improvers ETF
UPGD · ETF
About UPGD
- Issuer
- Invesco
- Tracks
- Bloomberg ANR Improvers Index
- Expense ratio
- 0.4%
- Assets under management
- $111.45M
- Inception
- May 19, 2006
- Asset class
- Equity
- Website
- invesco.com
UPGD key statistics
- Price-earnings ratio
- 0.00
- Average volume
- 9.97K
- Volume
- 247
- Open price
- $83.49
- High today
- $83.57
- Low today
- $83.57
- 52 Week high
- $84.73
- 52 Week low
- $70.85
Invesco Bloomberg Analyst Rating Improvers ETF (UPGD) at a glance
As of Oct 23, 2026, Invesco Bloomberg Analyst Rating Improvers ETF (UPGD) shares are priced at $83.57, giving the company a price-to-earnings ratio of 0.00.
Volume so far is 247 shares, below the average of 9.97K shares a day.
Over the past year Invesco Bloomberg Analyst Rating Improvers ETF has ranged from $70.85 to $84.73, and now sits 92% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- GTVHGolden Triangle Ventures$0.0002+100.00%
- TMSHTrans Global Assets$0.0003+20.00%
- RDARRaadr$0.0002+0.00%
- GPUSHyperscale Data$0.1689+34.05%
- SEIISharing Economy International$0.0002−33.33%
- ELMEElme Communities$1.77+0.57%
- SHFSSHF Holdings$0.1324−61.39%
- XXII22nd Century Group$0.1977−8.34%
- NBNDNetBrands$0.0006−40.00%
- NVDGraniteShares ETF Trust$4.19+0.96%
- HIRUHiru$0.0006+9.09%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.49−0.10%
- CTYCITY THERAPEUTICS$20.77+0.00%
- IAMIambic Therapeutics$14.26−2.79%
- AMROAmaero$5.84+7.75%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.30+0.29%
- TRXBTRex Bio$13.81−10.90%
- RTSNRetension Pharmaceuticals$15.25−1.61%
- PAXGUPine Tree Acquisition$10.01+0.05%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.13−0.77%
- ACCVAccelevation Holdings$12.38+1.06%
- RZAIROZE AI$10.92−1.89%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.